Shengwen Li

Title: Innovations by Shengwen Li: Pioneering Modified Clostridial Toxins

Introduction

Shengwen Li, based in Irvine, California, is a prolific inventor with a remarkable portfolio of 20 patents. His innovative work primarily focuses on modified Clostridial toxins, showcasing significant advancements in targeting and translocation capabilities.

Latest Patents

Among his latest innovations, Shengwen Li has developed two notable patents. The first is titled "Modified Clostridial toxins with enhanced targeting capabilities for endogenous Clostridial toxin receptor systems." This patent describes modified Clostridial toxins that incorporate a Clostridial toxin enzymatic domain, a translocation domain, and an enhanced binding domain. The invention also details polynucleotide molecules that encode these modified toxins and the methods for their production.

The second patent is related to "Modified Clostridial toxins with enhanced translocation capability and enhanced targeting activity." It elaborates on modified Clostridial toxins that again consist of a Clostridial toxin enzymatic domain, a translocation domain, and a translocation facilitating domain, along with an enhanced targeting domain. Similar to the first, this patent includes information on polynucleotide molecules and the methods for generating these innovative toxins.

Career Highlights

Shengwen Li's career includes significant contributions while working at Allergan, Inc. and Allergas, Inc. His expertise in biochemistry and related fields has enabled him to push the boundaries of scientific research and application in toxicology and therapeutic development.

Collaborations

Throughout his career, Shengwen has collaborated with notable colleagues, including Kei Roger Aoki and Lance Steward. These collaborative efforts have further enriched his innovative research, resulting in advancements that may significantly impact medical science and therapeutic methods.

Conclusion

Shengwen Li stands out as a leading innovator in the field of Clostridial toxins. With his extensive portfolio of patents and collaborations with industry peers, he continues to contribute valuable insights and advancements in therapeutic technologies. As his research progresses, the impact of his inventions is likely to be felt across various applications in medicine and biotechnology.